Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine co-administered with a booster dose of a combined diphtheria-tetanus- acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in healthy children aged 12-23 months

European Journal of Pediatrics

Volumn 166, Issue 8, 2007, Pages 857-864

  Zepp, Fred ^a   Behre, Ulrich ^b   Kindler, Klaus ^c   Laakmann, Karl Heinz ^d   Pankow Culot, Heidemarie ^b   Mannhardt Laakmann, Wilma ^a   Beckers, François ^e   Descamps, Dominique ^e   Willems, Paul ^e  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b Paediatric Office   (Germany)

^c Paediatric Office   (Germany)

^d Paediatric Office   (Germany)

^e GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Co administration; DTPa HBV IPV Hib booster; Immunogenicity; Measles mumps rubella varicella vaccine; Safety

Indexed keywords

CHICKENPOX MEASLES MUMPS RUBELLA VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; MMRV; POLIOMYELITIS VACCINE; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ARTICLE; CHICKENPOX; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GEOMETRY; HAEMOPHILUS INFLUENZAE TYPE B; HEPATITIS B VIRUS; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INFANT; MALE; MEASLES; MUMPS; NORMAL HUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RUBELLA; SEROCONVERSION;

ANALYSIS OF VARIANCE; ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; CHICKENPOX VACCINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; INFANT; MALE; MEASLES-MUMPS-RUBELLA VACCINE; PAIN; SKIN DISEASES; VACCINES, COMBINED;

EID: 34250878434     PISSN: 03406199     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00431-007-0506-z     Document Type: Article

References (24)

1. Australian Technical Advisory Group on Immunisation (ATAGI)/National Health and Medical Research Council (NHMRC) (2003) The Australian immunisation handbook, 8th edn. Australian Government Publishing Service, Canberra
2. Banz K, Wagenpfeil S, Neiss A, Hammerschmidt T, Wutzler P (2004) The burden of varicella in Germany: potential risks and economic impact. Eur J Health Econ 5:46-53
3. Boelle PY, Hanslik T (2002) Varicella in non-immune persons: incidence, hospitalization and mortality rates. Epidemiol Infect 129:599-606
4. Bonhoeffer J, Baer G, Muechleisen B (2005) Prospective surveillance of hospitalisations associated with varicella-zoster virus infections in children and adolescents. Eur J Pediatr 164:366-370
5. Centers for Disease Control and Prevention (1996) Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 45(RR-11):1-36
6. Centers for Disease Control and Prevention (1998) Varicella-related deaths among children-United States, 1997. MMWR Morb Mortal Wkly Rep 47:365-368
7. Centers for Disease Control and Prevention (1999) Prevention of varicella. Update recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 48(RR-6):1-5
8. Centers for Disease Control and Prevention (2006) Advisory Committee on Immunization Practices (ACIP). Provisional recommendations for the prevention of varicella. Available at: http://www.cdc.gov/nip/recs/provisional_recs/default. htm. Accessed 07 December 2006
9. Centers for Disease Control and Prevention (2006) Measles. In: Atkinson W, Hamborsky J, McIntyre L, Wolfe S (eds) Epidemiology and prevention of vaccine-preventable diseases, 9th edn. Public Health Foundation, Washington DC, pp 125-144
10. Comite Asesor de Vacunas de la Asociacion Espanola de Pediatria (CAVAEP) (2003) Childhood immunization schedule of the Spanish Association of Pediatrics. An Pediatr (Barc) 58:257-262
11. Gil A, San-Martin M, Carrasco P, Gonzalez A (2004) Epidemiology of severe varicella-zoster virus infection in Spain. Vaccine 22:3947-3951
12. Hollinger FB, Adam E, Heiberg DF, Melnick JL (1982) Response to hepatitis B vaccine in a young adult population. In: Szmuness W, Alter HJ, Maynard J (eds) Viral Hepatitis International Symposium. Franklin Institute Press, Philadelphia, PA, pp 451-466
13. Knuf M, Habermehl P, Zepp F, Mannhardt W, Kuttnig M, Muttonen P, Prieler A, Maurer H, Bisanz H, Tornieporth N, Descamps D, Willems P (2006) Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella- varicella vaccine in healthy children. Pediatr Infect Dis J 25:12-18
14. Meyer PA, Seward JF, Jumaan AO, Wharton M (2000) Varicella mortality: trends before vaccine licensure in the United States, 1970-1994. J Infect Dis 182:383-390
15. National Advisory Committee on Immunization (NACI) (2004) Update on varicella. Can Commun Dis Rep 30:1-26
16. Nolan T, McIntyre P, Roberton D, Descamps D (2002) Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine. Vaccine 21:281-289
17. Peltola H, Heinonen OP (1986) Frequency of true adverse reactions to measles-mumps-rubella vaccine. A double-blind placebo-controlled trial in twins. Lancet I:939-942
18. Rawson H, Crampin A, Noah N (2001) Deaths from chickenpox in England and Wales 1995-7: analysis of routine mortality data. BMJ 323:1091-1093
19. Robert Koch Institute (2004) Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: Juli 2004. Epidemiol Bull 30:235-250
20. Saenger R, Maechler G, Potreck M, Zepp F, Knuf M, Habermehl P, Schuerman L (2005) Booster vaccination with hexavalent DTPa-HBV-IPV/Hib vaccine in the second year of life is as safe as concomitant DTPa-IPV/Hib + HBV administered separately. Vaccine 23:1135-1143
21. Tichmann-Schumann I, Soemantri P, Behre U, Disselhoff J, Mahler H, Maechler G, Sänger R, Jacquet J-M, Schuerman L (2005) Immunogenicity and reactogenicity of four doses of diphtheria-tetanus-three-component acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccine coadministered with 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 24:70-77
22. World Health Organization (1993) Standard procedures for determining immunity to poliovirus using the micro-neutralization test. WHO/EPI/GEN 93.9
23. World Health Organization (2004) Measles vaccines. Wkly Epidemiol Rec 79:130-142
24. Zepp F, Steens JM (2001) Reactogenicity and immunogenicity of a combined measles, mumps, rubella (MMR) and varicella (V) vaccine, compared to concomitant injections of MMR+V in healthy children aged 12-24 months [abstract]. In: Program and abstracts of the 23rd International Congress of Pediatrics (Beijing, China)